Stay updated on Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAccess to the study record NCT02697630 (PEMDAC) on ClinicalTrials.gov now renders a 403 Forbidden error, replacing the previous study content. As a result, the study overview, eligibility criteria, locations, and results are not accessible to users.SummaryDifference17%

- Check20 days agoChange DetectedThe page now shows Revision: v3.7.0 in place of Revision: v3.6.6, indicating a new build/version of the page.SummaryDifference0.1%

- Check62 days agoChange DetectedThe page revision was bumped from v3.6.4 to v3.6.5. This indicates a minor update to the page build rather than changes to study content or user-facing features.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the entry; this reflects a minor update to the page metadata rather than a change to the study content.SummaryDifference0.1%

- Check98 days agoChange DetectedThe revision indicator on the page changes from v3.6.1 to v3.6.3. This reflects a minor site version update.SummaryDifference0.1%

- Check105 days agoChange DetectedRevision: v3.6.1 is now displayed, replacing v3.6.0. This update represents a minor page version upgrade that does not alter study content or results.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.